Evidence map›Paper›PMID 41365553›Full record

ArticleJournal of Korean medical science2025

Effect of Isoniazid Resistance on Treatment Outcome Among People With Pulmonary Tuberculosis in Korea.

Jong Min Lee, Hyung Woo Kim, Eung Gu Lee, Yeonhee Park, Sung Soo Jung, Jin Woo Kim, Jee Youn Oh, Heayon Lee, Seung Hoon Kim, Sun-Hyung Kim and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Real-world treatment outcomes of a 6-month fluoroquinolone-containing regimen for isoniazid mono-resistant pulmonary tuberculosis in Korea.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jong Min LeeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-9025-225X
Hyung Woo KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-8897-6598
Eung Gu LeeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-4938-5912
Yeonhee ParkDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-9537-1530
Sung Soo JungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.ORCID https://orcid.org/0000-0001-7990-3066
Jin Woo KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-6022-1292
Jee Youn OhDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-1219-0070
Heayon LeeDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-7389-2343
Seung Hoon KimDivision of Pulmonology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-0688-2783
Sun-Hyung KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.ORCID https://orcid.org/0000-0002-7623-0617
Jiwon LyuDepartment of Pulmonary and Critical Care Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.ORCID https://orcid.org/0000-0001-5988-1664
Sun Jung KwonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.ORCID https://orcid.org/0000-0002-0361-8629
Yun-Jeong JeongDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.ORCID https://orcid.org/0000-0001-9144-7403
Dojin KimDivision of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.ORCID https://orcid.org/0000-0002-1150-9588
Hyeon-Kyoung KooDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.ORCID https://orcid.org/0000-0002-1200-9892
Ganghee ChaeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Korea.ORCID https://orcid.org/0000-0002-7480-2634
Sun Young KyungDivision of Pulmonology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea.ORCID https://orcid.org/0000-0001-6822-1027
Sung Soon LeeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.ORCID https://orcid.org/0000-0001-6422-2313
Jae Seuk ParkDivision of Pulmonology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.ORCID https://orcid.org/0000-0001-9307-1155
Ju Sang KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-4433-231X
Jinsoo MinDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. minjinsoo@catholic.ac.kr.ORCID https://orcid.org/0000-0001-6091-518X

Funding

Korea Disease Control and Prevention AgencyKorea National Institute of Health 2022E200100Korea National Institute of Health 2025E200100
6 · The paper itself

Abstract

backgroundIsoniazid resistance is the most common type of ant-tuberculosis drug resistance, which is often neglected in clinical practice. This study aimed to evaluate the impact of isoniazid mono-resistant tuberculosis (Hr-TB) on the treatment outcomes of people with pulmonary tuberculosis.

methodsPeople with pulmonary tuberculosis were enrolled from the Korea Tuberculosis Cohort (KTBC) registry and the multicenter prospective cohort study of pulmonary tuberculosis (COSMOTB). Isoniazid resistance was confirmed using drug susceptibility test results. The primary outcome was an unfavorable outcome, which defined as comprising death, failure, loss-to-follow-up, still-on-treatment, and not-evaluated. Logistic regression analysis was conducted to evaluate effect of isoniazid resistance on treatment outcomes. We also compared 2-month sputum negative culture conversion rate and incidence of adverse events between Hr-TB and drug-susceptible tuberculosis.

resultsFrom the KTBC and COSMOTB databases, 10,482 and 758 participants were included, respectively. Compared to drug-susceptible tuberculosis, Hr-TB had higher rates of unfavorable outcome in the KTBC (45.8% vs. 37.0%,

conclusionIsoniazid resistance is significantly associated with unfavorable clinical outcomes.

Indexed as

Antitubercular AgentsIsoniazidTuberculosis, PulmonaryAdultAgedDrug Resistance, BacterialFemaleHumansLogistic ModelsMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisOdds RatioProspective StudiesRegistriesAntitubercular AgentsIsoniazidCohortIsoniazid ResistancePulmonary TuberculosisUnfavorable Outcome

Identifiers

PMID41365553
PMCPMC12685575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.